Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
1d
BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...
Shareholders request Human Rights Due Diligence to determine whether pharma companies do everything they can to increase drug ...
The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...
Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...
Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Hosted on MSN5d
Morgan Stanley Upgrades Gilead Sciences (GILD)Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback